Could a Two-Drug HIV pill work for TB patients?
NCT ID NCT06497465
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a two-drug HIV regimen (dolutegravir plus lamivudine) works as well as the standard three-drug regimen in people who also have tuberculosis and are on TB treatment. About 150 participants who have never taken HIV medication will be randomly assigned to one of three groups. The goal is to see if the simpler regimen can control HIV just as effectively while reducing the number of pills and potential side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dolutegravir and lamivudine (DTG/3TC)
- What this could lead to
- If successful, this could offer a simpler, lower-toxicity HIV treatment option for people also being treated for tuberculosis.
- What could go wrong
- This is a mid-stage trial with only 150 participants. The dual therapy may not suppress HIV as well as the standard three-drug regimen, and drug interactions with TB meds remain a concern.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CePClin - Center for Studies and Research in Infectious Diseases Ltda
RECRUITINGNatal, Rio Grande do Norte, 59.025-050, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
FIOCruz
RECRUITINGRio de Janeiro, Rio de Janeiro, 21040-360, Brazil
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Geral de Nova Iguaçu
RECRUITINGRio de Janeiro, Rio de Janeiro, 26210-190, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Instituto Tropical de Doenças Infecciosas Manaus
RECRUITINGManaus, Amazonas, 69040-000, Brazil
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
RDSS- Ricardo Diaz Solucoes Cientificas
RECRUITINGSão Paulo, São Paulo, 04037-030, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universidade Federal da Bahia
RECRUITINGSalvador, Estado de Bahia, 40110-160, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Can a more powerful antibiotic clear TB faster? a trial puts rifapentine to the test.
- Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
- Home care plus nutrition may cut post-hospital deaths in HIV — a trial puts it to the test
- Heavy drinking and risky sex: a text-based intervention aims to cut HIV risk
- Pharmacists on the front line: a new strategy to fight heart disease in people with HIV